Exicure, inc. announces termination of abbvie and ipsen collaboration agreements

Chicago--( business wire )--exicure, inc. (nasdaq: xcur) an early-stage biotechnology company historically focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets, today announced the termination of its collaboration agreements with abbvie, inc. (abbvie) and ipsen biopharm limited (ipsen).
XCUR Ratings Summary
XCUR Quant Ranking